Jesus Esquivel, MD, FACS to Present at 67th Society for Surgical Oncology Annual Cancer Symposium
SCHAUMBURG, Ill., Feb. 24, 2014 /PRNewswire-USNewswire/ -- Jesus Esquivel, MD, FACS, National Director of HIPEC Research and Medical Director, International Oncology Initiatives for Cancer Treatment Centers of America, has been selected to make two oral presentations at the 67th Society for Surgical Oncology Annual Cancer Symposium, taking place March 12-15, 2014 in Phoenix, Arizona. The symposium is a leading international scientific meeting that offers attendees the opportunity to learn about the latest advances in surgical oncology.
Dr. Esquivel's presentations both involve the Peritoneal Surface Disease Severity Score (PSDSS) and its potential as diagnostic aide in evaluating treatment options. His first presentation, titled "Evaluation of a new staging classification and a PSDSS in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination", examines ways of using the PSDSS as a determinant of current therapies in patients with mucinous appendiceal neoplasms with or without peritoneal dissemination. The findings were significant in that, they indicate that the PSDSS may serve as an important prognostic indicator and that can improve the selection of patients to receive an appropriate therapy from the time of diagnosis.
Dr. Esquivel will also share his findings of his study titled "The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution evaluation of the PSDSS in 1,048 patients with colorectal cancer with Peritoneal Carcinomatosis." This study explored the theory that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). The study results found that when a PSDSS score is determined prior to surgery it is capable of defining CRCPC populations who have a statistically-defined high or considerably lower likelihood of long-term survival following HIPEC. This finding implies that PSDSS can be useful in the decision to enter CRCPC patients into, and their stratification within, specific clinical trials.
"I am honored by the opportunity to present this research at the Society of Surgical Oncology's Cancer Symposium," said Dr. Esquivel. "Both of these studies represent- the collective efforts of a variety of surgical oncology experts with results that have direct practice implications and will effect patient's treatment options. We are excited about the effect that PSDSS can have in refining the diagnostic process and ultimately, assist in selecting the best treatment options for colorectal cancer patients."
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrative approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
SOURCE Cancer Treatment Centers of America